Cytek Biosciences (CTKB) Stock Forecast, Price Target & Predictions
CTKB Stock Forecast
Cytek Biosciences stock forecast is as follows: an average price target of $8.50 (represents a 29.77% upside from CTKB’s last price of $6.55) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
CTKB Price Target
The average price target for Cytek Biosciences (CTKB) is $8.50 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $8.50 to $8.50. This represents a potential 29.77% upside from CTKB's last price of $6.55.
CTKB Analyst Ratings
According to 4 Wall Street analysts, Cytek Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for CTKB stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 1 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Cytek Biosciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 13, 2024 | Dave Westenberg | Piper Sandler | - | - | 38.21% | 29.77% |
| Aug 17, 2022 | David Westenberg | Piper Sandler | - | - | 13.64% | 144.27% |
| May 15, 2022 | David Westenberg | Piper Sandler | - | - | 27.93% | 83.21% |
The latest Cytek Biosciences stock forecast, released on May 13, 2024 by Dave Westenberg from Piper Sandler, set a price target of $8.50, which represents a 38.21% increase from the stock price at the time of the forecast ($6.15), and a 29.77% increase from CTKB last price ($6.55).
Cytek Biosciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $8.50 |
| Last Closing Price | $6.55 | $6.55 | $6.55 |
| Upside/Downside | -100.00% | -100.00% | 29.77% |
In the current month, the average price target of Cytek Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Cytek Biosciences's last price of $6.55. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 13, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Dec 14, 2023 | Stephens | Positive | Initialise | |
| Oct 24, 2023 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Aug 17, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 19, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| May 15, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| May 12, 2022 | Goldman Sachs | Buy | Buy | Hold |
Cytek Biosciences's last stock rating was published by Piper Sandler on May 13, 2024. The company gave CTKB a "Overweight" rating, the same as its previous rate.
Cytek Biosciences Financial Forecast
Cytek Biosciences Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $58.60M | $48.00M | $49.69M | $37.09M | $48.34M | $40.48M | $40.16M | $35.06M | $38.89M | $34.38M | $30.41M |
| Avg Forecast | $81.17M | $65.77M | $61.28M | $57.41M | $69.59M | $58.09M | $54.67M | $49.66M | $61.49M | $50.70M | $49.53M | $43.59M | $56.58M | $55.48M | $45.71M | $47.15M | $50.22M | $43.29M | $39.63M | $32.51M | $36.42M | $33.37M | $28.27M |
| High Forecast | $82.40M | $66.77M | $62.21M | $58.29M | $70.65M | $58.97M | $55.50M | $49.90M | $62.10M | $51.49M | $50.28M | $44.25M | $57.44M | $55.48M | $46.41M | $47.86M | $50.98M | $43.29M | $39.63M | $32.51M | $36.42M | $33.37M | $28.27M |
| Low Forecast | $79.38M | $64.32M | $59.93M | $56.15M | $68.06M | $56.81M | $53.46M | $49.39M | $60.65M | $49.90M | $48.43M | $42.63M | $55.34M | $55.48M | $44.71M | $46.11M | $49.11M | $43.29M | $39.63M | $32.51M | $36.42M | $33.37M | $28.27M |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.04% | 0.87% | 1.09% | 0.79% | 0.96% | 0.94% | 1.01% | 1.08% | 1.07% | 1.03% | 1.08% |
Cytek Biosciences's average Quarter revenue forecast for Mar 24 based on 1 analysts is $43.59M, with a low forecast of $42.63M, and a high forecast of $44.25M. CTKB's average Quarter revenue forecast represents a -25.62% decrease compared to the company's last Quarter revenue of $58.60M (Dec 23).
Cytek Biosciences EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $3.32M | $-3.59M | $-9.13M | $-8.37M | $4.80M | $3.27M | $800.00K | $-1.24M | $936.00K | $2.71M | $3.90M |
| Avg Forecast | $96.31K | $78.04K | $72.71K | $68.13K | $82.58K | $68.93K | $64.86K | $58.93K | $72.96K | $60.15K | $58.77K | $51.72K | $67.14K | $65.83K | $54.24K | $55.94K | $59.59K | $1.99M | $1.82M | $1.50M | $1.68M | $1.54M | $1.30M |
| High Forecast | $97.78K | $79.23K | $73.81K | $69.16K | $83.83K | $69.97K | $65.85K | $59.21K | $73.69K | $61.10K | $59.66K | $52.50K | $68.16K | $65.83K | $55.07K | $56.79K | $60.50K | $1.99M | $1.82M | $1.50M | $1.68M | $1.54M | $1.30M |
| Low Forecast | $94.19K | $76.33K | $71.11K | $66.63K | $80.75K | $67.41K | $63.44K | $58.60K | $71.97K | $59.21K | $57.47K | $50.58K | $65.66K | $65.83K | $53.05K | $54.71K | $58.28K | $1.99M | $1.82M | $1.50M | $1.68M | $1.54M | $1.30M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 49.49% | -54.54% | -168.27% | -149.57% | 80.57% | 1.64% | 0.44% | -0.83% | 0.56% | 1.76% | 3.00% |
1 analysts predict CTKB's average Quarter EBITDA for Mar 24 to be $51.72K, with a high of $52.50K and a low of $50.58K. This is -98.44% lower than Cytek Biosciences's previous annual EBITDA (Dec 23) of $3.32M.
Cytek Biosciences Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $6.30M | $-6.46M | $-4.39M | $-6.81M | $3.53M | $1.67M | $-702.00K | $-2.16M | $-1.17M | $1.42M | $2.67M |
| Avg Forecast | $11.95M | $4.65M | $663.93K | $-1.33M | $15.05M | $6.97M | $7.08M | $3.54M | $14.16M | $1.53M | $-380.70K | $-3.32M | $3.98M | $2.92M | $1.59M | $2.99M | $5.64M | $1.64M | $1.64M | $-1.31M | $3.29M | $3.07M | $1.31M |
| High Forecast | $12.19M | $4.74M | $677.05K | $-1.29M | $15.35M | $7.11M | $7.22M | $5.90M | $19.83M | $1.56M | $-369.79K | $-3.22M | $4.06M | $2.98M | $1.62M | $3.05M | $5.75M | $1.64M | $1.64M | $-1.31M | $3.29M | $3.07M | $1.31M |
| Low Forecast | $11.61M | $4.51M | $644.91K | $-1.35M | $14.62M | $6.77M | $6.88M | $2.36M | $11.33M | $1.49M | $-388.22K | $-3.39M | $2.66M | $2.84M | $1.55M | $2.90M | $5.48M | $1.64M | $1.64M | $-1.31M | $3.29M | $3.07M | $1.31M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.58% | -2.21% | -2.75% | -2.28% | 0.63% | 1.01% | -0.43% | 1.64% | -0.35% | 0.46% | 2.03% |
Cytek Biosciences's average Quarter net income forecast for Mar 24 is $-3.32M, with a range of $-3.39M to $-3.22M. CTKB's average Quarter net income forecast represents a -152.69% decrease compared to the company's last Quarter net income of $6.30M (Dec 23).
Cytek Biosciences SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $21.90M | $22.43M | $25.15M | $23.23M | $19.54M | $16.85M | $17.02M | $14.51M | $15.24M | $12.30M | $9.74M |
| Avg Forecast | $29.23M | $23.68M | $22.06M | $20.67M | $25.06M | $20.92M | $19.68M | $17.88M | $22.14M | $18.25M | $17.83M | $15.69M | $20.37M | $19.97M | $16.46M | $16.98M | $18.08M | $15.59M | $14.27M | $11.71M | $13.11M | $12.02M | $10.18M |
| High Forecast | $29.67M | $24.04M | $22.40M | $20.99M | $25.44M | $21.23M | $19.98M | $17.97M | $22.36M | $18.54M | $18.10M | $15.93M | $20.68M | $19.98M | $16.71M | $17.23M | $18.36M | $15.59M | $14.27M | $11.71M | $13.11M | $12.02M | $10.18M |
| Low Forecast | $28.58M | $23.16M | $21.58M | $20.22M | $24.51M | $20.45M | $19.25M | $17.78M | $21.84M | $17.97M | $17.44M | $15.35M | $19.92M | $19.97M | $16.10M | $16.60M | $17.68M | $15.59M | $14.27M | $11.71M | $13.11M | $12.02M | $10.18M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.07% | 1.12% | 1.53% | 1.37% | 1.08% | 1.08% | 1.19% | 1.24% | 1.16% | 1.02% | 0.96% |
Cytek Biosciences's average Quarter SG&A projection for Mar 24 is $15.69M, based on 1 Wall Street analysts, with a range of $15.35M to $15.93M. The forecast indicates a -28.34% fall compared to CTKB last annual SG&A of $21.90M (Dec 23).
Cytek Biosciences EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $0.05 | $-0.05 | $-0.03 | $-0.05 | $0.03 | $0.01 | $-0.01 | $-0.02 | $-0.01 | - | $0.02 |
| Avg Forecast | $0.09 | $0.04 | $0.01 | $-0.01 | $0.11 | $0.05 | $0.05 | $0.03 | $0.11 | $0.01 | $-0.00 | $-0.03 | $0.03 | $0.02 | $0.01 | $0.02 | $0.04 | $0.01 | $0.01 | $-0.01 | $0.03 | $0.02 | $0.01 |
| High Forecast | $0.09 | $0.04 | $0.01 | $-0.01 | $0.12 | $0.05 | $0.05 | $0.04 | $0.15 | $0.01 | $-0.00 | $-0.02 | $0.03 | $0.02 | $0.01 | $0.02 | $0.04 | $0.01 | $0.01 | $-0.01 | $0.03 | $0.02 | $0.01 |
| Low Forecast | $0.09 | $0.03 | - | $-0.01 | $0.11 | $0.05 | $0.05 | $0.02 | $0.09 | $0.01 | $-0.00 | $-0.03 | $0.02 | $0.02 | $0.01 | $0.02 | $0.04 | $0.01 | $0.01 | $-0.01 | $0.03 | $0.02 | $0.01 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.61% | -2.15% | -2.69% | -2.23% | 0.61% | 0.80% | -0.42% | 1.61% | -0.43% | 0.19% | 2.04% |
According to 1 Wall Street analysts, Cytek Biosciences's projected average Quarter EPS for Mar 24 is $-0.03, with a low estimate of $-0.03 and a high estimate of $-0.02. This represents a -151.87% decrease compared to CTKB previous annual EPS of $0.05 (Dec 23).
Cytek Biosciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VAPO | Vapotherm | - | - | 5798.62% | Hold |
| APYX | Apyx Medical | - | - | 486.21% | Buy |
| INGN | Inogen | - | - | 177.19% | Buy |
| SGHT | Sight Sciences | - | - | 124.44% | Hold |
| LUNG | Pulmonx | - | - | 75.70% | Buy |
| RXST | RxSight | - | - | 56.39% | Buy |
| KIDS | OrthoPediatrics | - | - | 50.34% | Buy |
| LIVN | LivaNova | - | - | 37.37% | Buy |
| NPCE | NeuroPace | - | - | 32.78% | Buy |
| CTKB | Cytek Biosciences | - | - | 29.77% | Buy |
| OFIX | Orthofix Medical | - | - | 26.92% | |
| SRDX | Surmodics | - | - | 0.43% | Buy |